amifostine anhydrous has been researched along with paclitaxel in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (18.75) | 18.2507 |
| 2000's | 35 (72.92) | 29.6817 |
| 2010's | 4 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Glover, DJ | 1 |
| Forastiere, AA; Urba, SG | 1 |
| Pronk, LC; Schellens, JH; Verweij, J | 1 |
| Capizzi, RL; Johnson, CS; Lopez, MH; Paine, GD; Taylor, CW | 1 |
| Capizzi, RL; Fernandes, D; Johnson, CS; List, AF; Paine-Murrieta, GD; Taylor, CW; Wang, LM | 1 |
| Battaglia, A; Bonanno, G; Fattorossi, A; Leone, G; Mancuso, S; Menichella, G; Panici, PB; Perillo, A; Pierelli, L; Scambia, G | 1 |
| Belani, CP; Selvaggi, G | 1 |
| Batist, G; Blackstein, M; Bryce, C; Eisenhauer, E; Fisher, B; Gelmon, K; Iglesias, J; Mayer, L; Tolcher, A; Tomiak, E; Tomlinson, E; Yau, J; Zee, B | 1 |
| Bahlitzanakis, N; Froudarakis, M; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Retalis, G | 1 |
| Beyer, J; Dubiel, M; Hildebrandt, M; Krusch, A; Rick, O; Schleicher, J; Schwella, N; Serke, S; Siegert, W | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Prescott, LM | 1 |
| Beijnen, JH; Hoekman, K; Huijskes, RV; Nannan Panday, VR; Rosing, H; Van den Brande, J; Verheijen, RH; Vermorken, JB | 1 |
| Beyer, J; Rick, O; Schleicher, J; Schubart, H; Schwella, N; Siegert, W | 1 |
| Awada, A; Brassinne, C; de Valeriola, D; Freyer, G; Gil, T; Hennebert, P; Kerger, J; Piccart, M; Selleslags, J | 1 |
| Axelrod, RS; Chapman, AE; Curran, WJ; Deshields, M; Friedland, DP; Grubbs, S; Hauck, W; Rose, LJ; Werner-Wasik, M | 1 |
| Bahlitzanakis, N; Froudarakis, M; Koukourakis, GV; Koukourakis, MI; Kyrgias, G; Retalis, G; Romanidis, K | 1 |
| Senzer, N | 1 |
| Braaksma, M; Levendag, P | 1 |
| Ang, P; Ang, PT; Chew, L; Fong, KW; Foo, KF; Lee, KM; Leong, SS; Lim, SH; Ong, YK; Tai, BC; Tan, EH; Wee, J; Wilder-Smith, E | 1 |
| Biamonte, R; Di Vagno, G; Ferrandina, G; Ferrau', F; Gadducci, A; Greggi, S; Lorusso, D; Manzione, L; Pignata, S; Scambia, G; Tateo, S | 1 |
| Antonadou, D; Bolanos, N; Petridis, A; Sagriotis, A; Synodinou, M; Throuvalas, N | 1 |
| Baran, I; Coskun, H; Demiray, M; Evrensel, T; Gonullu, G; Kanat, O; Kurt, E; Manavoglu, O; Turan, OF; Zarifoglu, M | 1 |
| Almadrones, L; Cella, DF; Donnelly, J; Herzog, TJ; McGuire, WP; Moore, DH; Waggoner, SE | 1 |
| Antonadou, D; Bolanos, N; Petridis, A; Sagriotis, A; Synodinou, M; Throuvalas, N; Veslemes, M | 1 |
| Costello, R; Haddad, R; Posner, M; Weeks, L; Wirth, L | 1 |
| Beamon, K; Doroshow, JH; Forman, S; Longmate, J; Margolin, K; Morgan, R; Openshaw, H; Shibata, S; Slatkin, NE; Somlo, G; Synold, TW | 1 |
| Alberts, DS; Hallum, AV; Hannigan, EV; Jiang, C; Liu, PY; Markman, M; Scudder, SA; Smith, GB; Smith, HO; Wilczynski, SP | 1 |
| Banglore, M; Jaboin, J; Ord, R; Suntharalingam, M; Taylor, R; Van Echo, D; Wolf, J | 1 |
| Boezen, HM; Bos, AM; de Graaf, H; de Swart, CA; De Vos, FY; de Vries, EG; Schaapveld, M; van der Zee, AG; Willemse, PH | 1 |
| Axelrod, R; Byhardt, R; Komaki, R; Langer, C; Machtay, M; Movsas, B; Nicolaou, N; Sarna, L; Scott, C; Smith, C; Wasserman, T; Werner-Wasik, M | 1 |
| Ozcan Arican, G | 1 |
| Alberola, V; Juan, O; Rocher, A; Sánchez, A; Sánchez, JJ | 1 |
| Burges, A; du Bois, A; Heilmann, V; Hilpert, F; Richter, B; Rossner, D; Späthe, K; Stähle, A; Tomé, O | 1 |
| Amrein, PC; Clark, JR; Colevas, AD; Deschler, DG; Fabian, RL; Finkelstein, DM; McIntyre, JF; Posner, MR; Rocco, JW; Supko, JG; Wang, CC | 1 |
| Abdel-Wahab, M; Abitbol, A; Hamilton-Nelson, K; Harvey, M; Lewin, A; Markoe, A; Troner, M; Wu, J | 1 |
| Dai, D; Davies, S; Holmes, AM; Leslie, KK; Nguyen, T; Theele, DP; Verschraegen, C | 1 |
| Bot, BM; Garces, YI; Jett, JR; Kozelsky, TF; Mandrekar, SJ; Martens, JM; Moore, DF; Okuno, SH; Schild, SE; Soori, GS; Wender, DB | 1 |
| Christie, D; Kennedy, T; Law, A; Pellitteri, P; Wood, C; Yumen, O | 1 |
| Byhardt, R; Komaki, R; Langer, C; Machtay, M; Movsas, B; Nicolaou, N; Sarna, L; Swann, S; Wasserman, T; Werner-Wasik, M | 1 |
| Alvarez, RD; Berry, E; Buttin, BM; Lurain, JR; Matthews, KS; Schink, J; Singh, DK | 1 |
| Allen, A; Braschayko, P; Burke, E; Costello, R; Flynn, J; Haddad, R; Li, Y; Mahadevan, A; Posner, M; Sonis, S; Tishler, RB; Wirth, L | 1 |
| Beck, BB; Dai, D; Elmaoued, R; Fischer, E; Leslie, KK; Luo, W; Meng, X; Wu, F | 1 |
| Albain, K; Bae, K; Curran, WJ; Gore, EM; Komaki, R; Machtay, M; Movsas, B; Paulus, R; Sause, WT | 1 |
| Axelrod, RS; Bradley, JD; Buyyounouski, MK; Komaki, R; Langer, C; Lawrence, YR; Machtay, M; Movsas, B; Paulus, R; Smith, C; Wasserman, T; Werner-Wasik, M | 1 |
5 review(s) available for amifostine anhydrous and paclitaxel
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Experimental therapeutic approaches for recurrent head and neck cancer.
Topics: Amifostine; Animals; Antibodies, Monoclonal; Granulocyte-Macrophage Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Interferon-alpha; Interleukin-2; Paclitaxel; Photochemotherapy | 1995 |
Emerging drug treatments for solid tumours.
Topics: Amifostine; Antineoplastic Agents; Aziridines; Deoxycytidine; Gemcitabine; Humans; Indolequinones; Indoles; Neoplasms; Organoplatinum Compounds; Paclitaxel; Protein Kinase C; Topoisomerase I Inhibitors | 1996 |
Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytoprotection; Humans; Lung Neoplasms; Nervous System Diseases; Paclitaxel; Protective Agents; Randomized Controlled Trials as Topic | 1999 |
Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation-Protective Agents; Radiotherapy; Radiotherapy Dosage; Taxoids; Time Factors; Treatment Outcome | 2002 |
29 trial(s) available for amifostine anhydrous and paclitaxel
| Article | Year |
|---|---|
Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Amifostine; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fatigue; Female; Humans; Middle Aged; Nausea; Paclitaxel; Radiation-Protective Agents; Treatment Outcome; Vomiting | 1999 |
Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm, Residual; Neoplasms; Paclitaxel; Taxoids | 2000 |
PBPC mobilization with paclitaxel, ifosfamide, and G-CSF with or without amifostine: results of a prospective randomized trial.
Topics: Adult; Amifostine; Antigens, CD34; Blood Specimen Collection; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Ifosfamide; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Pilot Projects; Prospective Studies | 2001 |
Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Ifosfamide; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prospective Studies; Radiation-Protective Agents; Taxoids | 2001 |
Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Therapy, Combination; Female; Humans; Middle Aged; Neutrophils; Paclitaxel; Pilot Projects; Survival Rate; Taxoids; Vomiting | 2002 |
Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy.
Topics: Acute Disease; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Esophagus; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Radiation-Sensitizing Agents; Survival Rate | 2002 |
Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation-Protective Agents; Radiotherapy; Radiotherapy Dosage; Taxoids; Time Factors; Treatment Outcome | 2002 |
A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Cytoprotection; Deoxycytidine; Esophagitis; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiation Injuries; Radiation-Protective Agents | 2002 |
Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Cytoprotection; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Radiotherapy, Conformal; Tomography, X-Ray Computed; Xerostomia | 2002 |
Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Double-Blind Method; Esophagitis; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Radiation Injuries; Radiation-Protective Agents; Treatment Outcome | 2003 |
Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Erythrocyte Count; Female; Humans; Infusions, Intravenous; Middle Aged; Mouth Mucosa; Neutropenia; Ovarian Neoplasms; Paclitaxel; Radiation-Protective Agents; Stomatitis; Thrombocytopenia | 2003 |
Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Paclitaxel; Radiation Injuries; Radiation Pneumonitis; Radiation-Protective Agents; Radiotherapy Dosage; Stomatitis; Treatment Outcome | 2003 |
Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cytoprotection; Female; Heart Diseases; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Prospective Studies; Protective Agents | 2003 |
Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neurologic Examination; Paclitaxel; Peripheral Nervous System Diseases; Radiation-Protective Agents; Treatment Outcome | 2003 |
Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.
Topics: Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation Injuries; Radiation Pneumonitis; Radiation-Protective Agents; Radiation-Sensitizing Agents | 2003 |
Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Stomatitis; Xerostomia | 2003 |
Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2005 |
The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mucous Membrane; Paclitaxel; Radiotherapy Dosage | 2004 |
A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neuroprotective Agents; Neutropenia; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2005 |
Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deglutition Disorders; Dose Fractionation, Radiation; Esophagitis; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Radiation Injuries; Radiation-Protective Agents; Survival Analysis; Treatment Outcome | 2005 |
Influence of the cyto-protective agent amifostine on the pharmacokinetics of low-dose Paclitaxel.
Topics: Amifostine; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Paclitaxel; Radiation-Protective Agents | 2005 |
Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AG
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Humans; Neuroprotective Agents; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Placebos; Radiation-Protective Agents | 2005 |
Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Risk Assessment; Survival Rate; Treatment Outcome | 2005 |
Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel | 2005 |
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality Control; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topotecan | 2007 |
Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Male; Middle Aged; Mucositis; Paclitaxel; Prospective Studies; Radiation Injuries; Radiation-Protective Agents; Radiotherapy Dosage; Xerostomia | 2007 |
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Cytokines; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Stomatitis; Survival Rate; Xerostomia | 2009 |
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Radiotherapy Dosage; Relative Biological Effectiveness; Retrospective Studies; Survival Analysis; Treatment Failure; Vinblastine | 2012 |
The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel | 2013 |
15 other study(ies) available for amifostine anhydrous and paclitaxel
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
New approaches to the chemotherapy of melanoma.
Topics: Alkaloids; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Daunorubicin; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Paclitaxel; Procarbazine; Tamoxifen; Taurine; Thiotepa; Vincristine; Vindesine | 1991 |
Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results.
Topics: Amifostine; Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Mice; Mice, SCID; Ovarian Neoplasms; Paclitaxel; Radiation-Protective Agents; Tumor Cells, Cultured | 1996 |
Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.
Topics: Amifostine; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Death; Cytoprotection; Female; Fibroblasts; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Mice; Mice, SCID; Ovarian Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1997 |
In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue.
Topics: Amifostine; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Cell Cycle; Cell Division; Cells, Cultured; Docetaxel; Doxorubicin; Etoposide; Hematopoietic Stem Cells; Humans; Leukocytes, Mononuclear; Paclitaxel; Taxoids; Time Factors | 1998 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
Highlights of the Eighth European Cancer Conference.
Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasms; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Taxoids; Vinblastine; Vinorelbine | 1995 |
Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Interactions; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Radiation-Protective Agents; Radiation-Sensitizing Agents | 2001 |
Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine.
Topics: Adult; Amifostine; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Synergism; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Narcotics; Neurons; Paclitaxel; Peripheral Nervous System Diseases; Radiation-Protective Agents; Time Factors | 2004 |
Cytoprotective effects of amifostine and cysteamine on cultured normal and tumor cells treated with paclitaxel in terms of mitotic index and 3H-thymidine labeling index.
Topics: Amifostine; Animals; Antineoplastic Agents, Phytogenic; Cysteamine; Fibroblasts; HeLa Cells; Humans; Mice; Mice, Inbred BALB C; Mitotic Index; Paclitaxel; Radiation-Protective Agents; Thymidine; Tumor Cells, Cultured | 2005 |
A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer.
Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Endometrial Neoplasms; Female; Humans; Mice; Mice, Nude; Paclitaxel; Proto-Oncogene Proteins c-jun; Xenograft Model Antitumor Assays | 2005 |
Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deglutition; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Quality of Life; Radiation-Protective Agents; Sexual Behavior; Socioeconomic Factors; Treatment Outcome; Weight Loss | 2008 |
An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Outpatients; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Retrospective Studies | 2009 |
Amifostine enhancement of the anti-cancer effects of paclitaxel in endometrial cancer is TP53-dependent.
Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Separation; Drug Synergism; Endometrial Neoplasms; Female; Flow Cytometry; Humans; Mice; Mice, Nude; Mutation; Paclitaxel; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2010 |